Proactive Investors - Run By Investors For Investors

Tekcapital: Overlooked and under-appreciated; so when will the market turn?

The company helps commercialise innovations developed in universities around the world. The shares are trading at a 40% discount to the value of its current basket of investments
ai graphic
The current portfolio includes nine firms that are at technology’s cutting edge, three of which are particularly perky

There’s a myth perpetuated by the ill-informed that stock markets are efficient arbiters of value.

For this to be the case investors need to be in possession of all the facts as they pertain to the constituent parts of said market.

Often information isn’t hidden from view, it is simply overlooked or ignored.

In other words, a little digging can (and often does) go a long way to establishing the true picture of an individual investment.

Lack of understanding

Lack of understanding of what’s hot and what’s not tends to lead to bipolar peaks and troughs for small-cap shares that are largely driven by misinformation.

This is bad news if you are the chief executive of a well-run AIM company struggling against a mass of selling, pulling out whatever’s left of your hair while railing against the inequity of your predicament.

However, it is much better news if you are a savvy investor that’s done some in-depth research - for the CEO’s painful problem presents an opportunity.

With this in mind, it might be worth taking a look at Tekcapital PLC (LON:TEK), which helps commercialise innovations developed in universities around the world.

University spin-outs

It spins out the intellectual property (IP) into separate companies and finds management to help capitalise on and commercialise the IP.

The current portfolio includes nine firms that are at technology’s cutting edge, three of which are particularly perky.

TekCapital also has a services business that generated revenues of almost £500,000 in the last six months.

Its shares have dropped from a 2018 peak of 25p in January to 11p today. Does the news flow support that kind of movement? Probably not, but this is AIM, remember.

It means the stock is now trading at a more than 40% discount to the net asset value, and an even greater deficit to its peer group.

Unloved gems

For chairman Dr Clifford Gross this is bound to be a source of irritation; however, the lowly valuation may be an opportunity for investors looking for unloved gems.

Remember, do your own research; don’t take what’s written here as gospel.

Hopefully, what you’ll find is a company that has three significant investments in businesses targeting markets worth £1bn-plus, with management teams that have experience at Fortune 1000 organisations.

READ: TEKCAPITAL HIRES OOZE QUALITY 

Any one of those businesses has the potential to be considerably more valuable than Tekcapital itself, analysts reckon.

Bellascura, for instance, with its CURV portable oxygen concentrator, is tapping into a medical devices sector that according to Knowledge Sourcing Intelligence could be worth over £1.5bn a year by 2021.

Huge market potential 

Even with a small sliver of those revenues, you have a business worth substantially more than it is today.

Bellascura’s last fundraise gave the business a post-money valuation of US$4.3mln, or £3.3mln. Tek’s 33% stake is therefore worth £1mln, or around 20% of its current market capitalisation.

It also holds 97.5% of Salarius, which owns a patented manufacturing process for producing low-sodium salt, a market expected to be worth £1.4bn by 2025.

And Tekcapital owns a 100% stake in Lucyd, which is developing smartglasses, tapping into a sector already turning over £3bn.

Salty opportunity

Salarius, Lucyd and the remainder of the portfolio are valued at the cost or value of the acquired intellectual property plus expenses, according to a note produced by Align Research (link here). In other words, TekCapital has taken a very conservative approach to assessing the worth of its portfolio.

And as Align analyst Richard Gill points out: “An uplift in the valuation of any one additional portfolio company, driven by a fundraising or other value event, could have a significant impact on the balance sheet and increase net asset value further.

“In this respect, we have already demonstrated above the potential uplift should the recent director purchase in Salarius be accounted for in the valuation.”

So, that acquisition of stock by CEO Victor Manazanilla implied a potential market worth of £1.5mln.

On the issue of value, it is worth doubling back to take a closer look at Bellascura – or more particularly a peer of the company.

Benchmark for value?

Nasdaq-listed Inogen (NASDAQ:INGN) develops, manufactures and markets oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Granted it is revenue generating: the company turned over £75mln last quarter and expects to make around £270mln this year.

But with a market capitalisation of £3.7bn, you can see how highly investors prize new innovative companies with transformational technology.

In the case of Inogen, it is trading on 14-times sales or a price-to-earnings multiple of almost 160 times.

“While applying this kind of valuation to Belluscura isn’t appropriate given its early stage of development, it does go to show the opportunities available in the sector,” points out Align’s Gill.

View full TEK profile View Profile

Tekcapital PLC Timeline

Related Articles

Crops
December 05 2018
Markets for both antennas and water systems are set to grow strongly over the coming years
E-Learning
November 16 2018
The e-learning specialist upgraded its long-term goals to run-rate revenues of £200mln and run-rate underlying earnings of at least £55mln by 2021, an increase of around 100%
machines
February 04 2019
“We continue to focus on further strengthening our engineering capability and optimising quality management to meet the expected growth in demand for driver monitoring systems,” chief executive Ken Kroeger.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use